36cb5dc0
2023-06-30
哪里Get This Free Report?
Moderna: Declining Performance And Relative Weakness
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":193036671926344,"tweetId":"193036671926344","gmtCreate":1688137921907,"gmtModify":1688137923351,"author":{"id":3573014764681345,"idStr":"3573014764681345","authorId":3573014764681345,"authorIdStr":"3573014764681345","name":"36cb5dc0","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>哪里Get This Free Report?</p></body></html>","htmlText":"<html><head></head><body><p>哪里Get This Free Report?</p></body></html>","text":"哪里Get This Free Report?","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/193036671926344","repostId":2347310111,"repostType":2,"repost":{"id":"2347310111","kind":"highlight","pubTimestamp":1688115780,"share":"https://www.laohu8.com/m/news/2347310111?lang=&edition=full","pubTime":"2023-06-30 17:03","market":"sg","language":"en","title":"Moderna: Declining Performance And Relative Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2347310111","media":"Ryan Hasson","summary":"Moderna's value has declined by over 75% from its peak as the world moves on from the COVID-19 pandemic, leading to concerns about its investment appeal.","content":"<html><body><div>\n<p><img height=\"667\" src=\"https://www.marketbeat.com/logos/articles/med_20230629145304_moderna-declining-performance-and-relative-weaknes.jpg\" width=\"1000\"/></p><div><h2>Key Points</h2><ul>\n<li><strong>Moderna's stock has retraced over 75% from its peak as COVID-19 cases decline globally.</strong></li>\n<li><strong>Relative weakness in Moderna compared to the biotechnology sector raises concerns for investors.</strong></li>\n<li><strong>Anticipated earnings and sales declines further dampen Moderna's investment appeal at this time.</strong></li>\n<li><strong>5 stocks we like better than Moderna</strong></li></ul></div>\n<p>Moderna <span>NASDAQ: MRNA<span></span></span> was the top-performing stock in the S&P 500 not too long ago when the company joined the index in mid-2021. At its peak in 2021, the company's value soared to $187 billion as COVID-19 cases surged around the globe. However, as the world moves on from the pandemic that swept the globe, shares of MRNA have retraced over 75% to a current price of $122 per share and market capitalization of $47 billion.</p>\n<p>MRNA has traded near crucial support around $120 for over a year after experiencing a sharp decline off the highs. Could a break away from support confirm recovery and turnaround for the stock? Or should investors stay away due to the stock's relative weakness over the previous year?</p>\n<h2>Moderna vs. The <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotechnology ETF (IBB)</h2>\n<p><img height=\"369\" loading=\"lazy\" src=\"https://www.marketbeat.com/logos/articles/med_20230629122911_screenshot-2023-06-29-121344.jpg\" width=\"915\"/></p>\n<p>Moderna is the sixth largest holding in the iShares Biotechnology ETF <span>NASDAQ: IBB<span></span></span>, weighing 3.83%. Moderna Shares have lagged significantly behind the biotechnology sector over the previous year. YTD, the IBB is down 4%, while MRNA is down almost 32%. Over a year, the IBB is up 6.78%, while MRNA is down 14.18%. The relative weakness in MRNA is a bearish signal, and until the stock can break the trend of underperformance, it remains guilty until proven innocent.</p>\n<h2>A Way Forward Without The Covid Vaccine</h2>\n<p><img height=\"320\" loading=\"lazy\" src=\"https://www.marketbeat.com/logos/articles/med_20230629123048_screenshot-2023-06-29-133031.jpg\" width=\"915\"/></p>\n<p>Moderna obliterated earnings estimates as the share price soared to new heights during the pandemic. The company, one of the pioneers behind the new messenger RNA platform, was at the forefront of developing and supplying the COVID-19 vaccine globally. However, as cases of the virus have plummeted around the globe, and the world attempts to move forward, Moderna's earnings have taken a hit.</p><ins></ins><br/>\n<p>The company recently said it plans to use its MRNA technology advancements to offer a new set of life-saving vaccines by 2030. Specifically, the company intends to provide vaccines targeting cancer, heart disease, and several other conditions.</p>\n<p>A spokesperson for the company, and Chief Medical Officer, Dr. Paul Burton, said: \"I think what we have learned in recent months is that if you ever thought that mRNA was just for infectious diseases, or just for Covid, the evidence now is that that's absolutely not the case. It can be applied to all sorts of disease areas; we are in cancer, infectious disease, cardiovascular disease, autoimmune diseases, rare disease.\" He added that studies on shots for the above-mentioned disease areas had shown significant promise.</p>\n<h2>Taking A Look At Moderna's Fundamentals</h2>\n<p>The company's first-quarter performance beat expectations, although it experienced a significant decline compared to the previous year. Moderna reported $0.19 per share, beating expectations of ($1.75). However, profits dropped by 98%, and sales fell by 69% to $1.86 billion.</p>\n<p>Analysts anticipate further declines for the company as the demand declines for Covid vaccinations. Analysts expect a loss of $3.97 per share for the second quarter and a sales drop of 93% to $346 million, compared to the previous year's earnings of $5.24. The company expects sales to be between $200 to $300 million for the current period.</p>\n<h2>Insiders Continue To Sell</h2>\n<p><img height=\"298\" loading=\"lazy\" src=\"https://www.marketbeat.com/logos/articles/med_20230629123448_screenshot-2023-06-29-133431.jpg\" width=\"915\"/></p>\n<p>Over the last three years, insiders have not purchased shares in the company. Since Q2 2020, insiders have consistently sold stock each quarter and, in total, have sold about $1.8 billion during that period. The lengthy trend of insider selling and lack of or non-existent purchases made by insiders will be a worrying sign for investors mulling over an investment in the company.</p>\n<h2>Is Now The Right Time To Invest In Moderna?</h2>\n<p>Considering the stock's current position near critical support levels and its trading below key moving averages, including the 200-day Simple Moving Average (SMA) and the 50-day SMA, the prevailing trend indicates weakness and a higher likelihood of further downside. Moreover, the chart demonstrates relative weakness and lacks a favorable risk-to-reward setup.</p>\n<p>With the anticipated significant decline in earnings and sales for the second quarter, the investment appeal of Moderna at this time is diminished.</p><h2>Should you invest $1,000 in Moderna right now?</h2><p>Before you consider Moderna, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.</p><p>While Moderna currently has a \"Hold\" rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here <span aria-hidden=\"true\"></span></p><div><div><div><img decoding=\"async\" height=\"209\" loading=\"lazy\" src=\"https://www.marketbeat.com/logos/premium-reports/small_20230308081034_reportpreview2023-02-best-high-yield-dividend-stoc.png\" width=\"170\"/><div></div></div><div><div><div>Ten Starter Stocks For Beginners to Buy Now</div><p>Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.</p>Get This Free Report</div></div></div></div><br/><div></div>\n</div></body></html>","source":"marketbeat_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna: Declining Performance And Relative Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna: Declining Performance And Relative Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-06-30 17:03 GMT+8 <a href=https://www.marketbeat.com/originals/moderna-declining-performance-and-relative-weakness/><strong>Ryan Hasson</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\nModerna's stock has retraced over 75% from its peak as COVID-19 cases decline globally.\nRelative weakness in Moderna compared to the biotechnology sector raises concerns for investors.\n...</p>\n\n<a href=\"https://www.marketbeat.com/originals/moderna-declining-performance-and-relative-weakness/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BNTX":"BioNTech SE","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK4501":"段永平概念","BK4139":"生物科技","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4588":"碎股","MRNA":"Moderna, Inc.","BK4532":"文艺复兴科技持仓","IBB":"生物科技指数ETF-iShares Nasdaq"},"source_url":"https://www.marketbeat.com/originals/moderna-declining-performance-and-relative-weakness/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2347310111","content_text":"Key Points\nModerna's stock has retraced over 75% from its peak as COVID-19 cases decline globally.\nRelative weakness in Moderna compared to the biotechnology sector raises concerns for investors.\nAnticipated earnings and sales declines further dampen Moderna's investment appeal at this time.\n5 stocks we like better than Moderna\nModerna NASDAQ: MRNA was the top-performing stock in the S&P 500 not too long ago when the company joined the index in mid-2021. At its peak in 2021, the company's value soared to $187 billion as COVID-19 cases surged around the globe. However, as the world moves on from the pandemic that swept the globe, shares of MRNA have retraced over 75% to a current price of $122 per share and market capitalization of $47 billion.\nMRNA has traded near crucial support around $120 for over a year after experiencing a sharp decline off the highs. Could a break away from support confirm recovery and turnaround for the stock? Or should investors stay away due to the stock's relative weakness over the previous year?\nModerna vs. The iShares Biotechnology ETF (IBB)\n\nModerna is the sixth largest holding in the iShares Biotechnology ETF NASDAQ: IBB, weighing 3.83%. Moderna Shares have lagged significantly behind the biotechnology sector over the previous year. YTD, the IBB is down 4%, while MRNA is down almost 32%. Over a year, the IBB is up 6.78%, while MRNA is down 14.18%. The relative weakness in MRNA is a bearish signal, and until the stock can break the trend of underperformance, it remains guilty until proven innocent.\nA Way Forward Without The Covid Vaccine\n\nModerna obliterated earnings estimates as the share price soared to new heights during the pandemic. The company, one of the pioneers behind the new messenger RNA platform, was at the forefront of developing and supplying the COVID-19 vaccine globally. However, as cases of the virus have plummeted around the globe, and the world attempts to move forward, Moderna's earnings have taken a hit.\nThe company recently said it plans to use its MRNA technology advancements to offer a new set of life-saving vaccines by 2030. Specifically, the company intends to provide vaccines targeting cancer, heart disease, and several other conditions.\nA spokesperson for the company, and Chief Medical Officer, Dr. Paul Burton, said: \"I think what we have learned in recent months is that if you ever thought that mRNA was just for infectious diseases, or just for Covid, the evidence now is that that's absolutely not the case. It can be applied to all sorts of disease areas; we are in cancer, infectious disease, cardiovascular disease, autoimmune diseases, rare disease.\" He added that studies on shots for the above-mentioned disease areas had shown significant promise.\nTaking A Look At Moderna's Fundamentals\nThe company's first-quarter performance beat expectations, although it experienced a significant decline compared to the previous year. Moderna reported $0.19 per share, beating expectations of ($1.75). However, profits dropped by 98%, and sales fell by 69% to $1.86 billion.\nAnalysts anticipate further declines for the company as the demand declines for Covid vaccinations. Analysts expect a loss of $3.97 per share for the second quarter and a sales drop of 93% to $346 million, compared to the previous year's earnings of $5.24. The company expects sales to be between $200 to $300 million for the current period.\nInsiders Continue To Sell\n\nOver the last three years, insiders have not purchased shares in the company. Since Q2 2020, insiders have consistently sold stock each quarter and, in total, have sold about $1.8 billion during that period. The lengthy trend of insider selling and lack of or non-existent purchases made by insiders will be a worrying sign for investors mulling over an investment in the company.\nIs Now The Right Time To Invest In Moderna?\nConsidering the stock's current position near critical support levels and its trading below key moving averages, including the 200-day Simple Moving Average (SMA) and the 50-day SMA, the prevailing trend indicates weakness and a higher likelihood of further downside. Moreover, the chart demonstrates relative weakness and lacks a favorable risk-to-reward setup.\nWith the anticipated significant decline in earnings and sales for the second quarter, the investment appeal of Moderna at this time is diminished.Should you invest $1,000 in Moderna right now?Before you consider Moderna, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.While Moderna currently has a \"Hold\" rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report","news_type":1},"isVote":1,"tweetType":1,"viewCount":798,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":22,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/193036671926344"}
精彩评论